Enveric Biosciences, Inc.

Equities

ENVB

US29405E2081

Biotechnology & Medical Research

Delayed Nasdaq Other stock markets 01:21:08 2024-05-23 pm EDT			5-day change	1st Jan Change
0.83 ^USD	0.00%		-7.78%	-36.15%

May. 14	Firefly Neuroscience Names David Johnson Executive Chairman, Following WaveDancer Merger	MT
May. 14	Enveric Biosciences Signs $66.5 Million Non-Binding Term Sheet with Mindbio Therapeutics to Out-License Novel Psilocin Prodrug Candidate for Mental Health Disorders	CI

Unlocking New Horizons: Enveric Biosciences’ Strategic Moves in Biotechnology [Microdose]

April 30, 2024 at 11:51 am EDT

Press Releases Unlocking New Horizons: Enveric Biosciences' Strategic Moves in Biotechnology [Microdose]

ByEnvericApril 30, 2024No Comments

In a significant stride toward transforming the landscape of joint disease treatment, Enveric Biosciences has inked two non-binding term sheets with a yet undisclosed biotechnology company. This promising collaboration is poised to steer the future of both pharmaceutical and non-pharmaceutical applications using innovative cannabinoid-COX-2 conjugate compounds. Situated in Cambridge, Massachusetts, Enveric's latest move aligns with its robust agenda of pushing the boundaries in medical biotechnology.

Full article >>

Attachments

Original Link
Permalink

Disclaimer

Enveric Biosciences Inc. published this content on 30 April 2024 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 30 April 2024 15:50:05 UTC.

Latest news about Enveric Biosciences, Inc.

Firefly Neuroscience Names David Johnson Executive Chairman, Following WaveDancer Merger	May. 14	MT
Enveric Biosciences Signs $66.5 Million Non-Binding Term Sheet with Mindbio Therapeutics to Out-License Novel Psilocin Prodrug Candidate for Mental Health Disorders	May. 14	CI
Enveric Biosciences, Inc. Announces Signing of Non-Binding Term Sheet with Undisclosed License to Patented Methods of Treating Breast and Other Cancers Using Cannabinoids	May. 08	CI
Enveric Biosciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 26	CI
Sector Update: Health Care Stocks Rise Late Afternoon	Mar. 19	MT
Sector Update: Health Care Stocks Higher in Tuesday Afternoon Trading	Mar. 19	MT
Enveric Biosciences Signs Licensing Term Sheets for Joint Disease Treatment Compounds; Shares Rise	Mar. 19	MT
Wall Street Set to Open Lower Ahead of Two-Day Fed Meeting; Housing Starts Surge Higher Than Expected	Mar. 19	MT
Enveric Biosciences Signs Non-Binding Term Sheets to Pursue the Exclusive Out-Licensing of New Chemical Entities for Pharmaceutical and Non-Pharmaceutical Applications in Joint Disease	Mar. 19	CI
Enveric Biosciences Issues 228,690 Shares in Direct Offering	Mar. 11	MT
Top Midday Gainers	Feb. 29	MT
Wall Street Set to Open Higher Thursday as Inflation Data Meets Forecasts	Feb. 29	MT
Investors Await Slate of Economic Data as US Futures Move Lower in Thursday's Premarket Session	Feb. 29	MT
Sector Update: Health Care Stocks Rise in Late Afternoon	Feb. 23	MT
Sector Update: Health Care Stocks Advance Friday Afternoon	Feb. 23	MT
Enveric Biosciences Surging on Plans to Sell Cannabinoid IP Portfolio, Focus Shift to Psilocin Therapies	Feb. 23	MT
Enveric Biosciences Unveils Library of Preclinical Compounds Across Multiple Distinct Molecule Classes Targeting Mental Health Disorders	Feb. 21	CI
HC Wainwright Initiates Enveric Biosciences With Buy Rating, Price Target is $10	Jan. 30	MT
Enveric Biosciences Updates Key Data Underpinning Selection of EB-003 as Lead Drug Candidate from EVM301 Series	Jan. 03	CI
Enveric Bioscience Generates $1.8 Million as Investors Exercise Warrants	Dec. 29	MT
Sector Update: Health Care Stocks Rise in Late Afternoon	Dec. 28	MT
Health Care Up on Defensive Bias -- Health Care Roundup	Dec. 28	DJ
Enveric Biosciences Selects EB-003 as Lead Drug Candidate from EVM301 Series	Dec. 28	CI
Enveric Biosciences Selects EB-003 as Lead Drug Candidate to Treat Mental Health Disorders	Dec. 28	MT
Enveric Biosciences Selects Development Candidates from Evm301 Series Based on Potential to Minimize or Eliminate the Hallucinogenic Effect of Psychedelic-Derived Compounds	Dec. 05	CI

Chart Enveric Biosciences, Inc.

Duration

Period

More charts

Company Profile

Enveric Biosciences, Inc. is a biotechnology company. The Company is engaged in the development of novel neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety and addiction disorders. The Company, through Psybrary has created a robust intellectual property (IP) portfolio of new chemical entities for specific mental health indications. Its lead program, the EVM201 Series, comprises synthetic prodrugs of the active metabolite, psilocin. It is developing the first product from the EVM201 Series, EB-002, for the treatment of psychiatric disorders. The Company is also advancing its second program, the EVM301 Series, EB 003, which is an approach to the treatment of difficult-to-address mental health disorders. Within the Psybrary, it has three different types of molecules, Generation 1 (classic psychedelics), Generation 2 (pro-drugs), and Generation 3 (new chemical entities). It has created over 1,000 novel psychedelic molecular compounds and derivatives.

Sector

Biotechnology & Medical Research

Calendar

2024-05-27 - Annual General Meeting

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

0.83 USD

Average target price

9 USD

Spread / Average Target

+984.34%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
ENVERIC BIOSCIENCES, INC.	-36.15%	6.05M
MODERNA, INC.	+64.74%	62.59B
IQVIA HOLDINGS INC.	-1.50%	41.18B
LONZA GROUP AG	+44.76%	40.29B
CELLTRION, INC.	-8.93%	27.9B
ICON PUBLIC LIMITED COMPANY	+13.32%	26.21B
ALNYLAM PHARMACEUTICALS, INC.	-21.78%	19.09B
BIO-TECHNE CORPORATION	+4.90%	13.08B
UNITED THERAPEUTICS CORPORATION	+25.48%	12.26B
MEDPACE HOLDINGS, INC.	+28.44%	12.05B

Other Biotechnology & Medical Research